Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- MSD’s Alvarez Moved Up to Chair of PhRMA Japan Committee
February 13, 2014
- Prof. Tsuchiya Slams Kowa’s Livalo Trademark Suit
February 10, 2014
- July-September Generic Share at 43.1% under New Formula: JGA
February 6, 2014
- JPWA to File Notification to Form Cartel for Uniform Tax Display Method
January 31, 2014
- JPMA Drafting New Rules that Would Restrict Grants and Endowments by Drug Makers to Research Not Involving Their Own Products
January 28, 2014
- Medwatcher Raps Ministry Subcommittees’ Conclusion on HPV Vaccine Side Effects
January 27, 2014
- Generic Industry Can’t Afford “Backsliding” Following FY2014 NHI Pricing Reform: JGA President Yoshida
January 27, 2014
- Dr Teshirogi of JPMA Expresses Concern About Impact of New Price Reduction Rule on Stable Supplies of Long-Listed Drugs, Generics
January 17, 2014
- Generic Makers Likely to Disclose Payments to Medical Institutions from Early May
January 15, 2014
- JPWA Chair Weighs Cartel Deal to Unify Tax Display Methods after Sales Levy Hike
January 14, 2014
- Next Drug Price Revision Won’t Help Promote Generic Use, JGA President Says
January 9, 2014
- Japan CRO Association Announces Report on Quality Assurance of Subcontracted Services
January 9, 2014
- New Price Cut for Long-Listed Products “Harsh,” Needs Follow-Up Review: FPMAJ Chair Naito
January 1, 2014
- New Price Cut Rule for Long-Listed Products Will Wreak Havoc on Pharmas: FPMAJ Chair
December 27, 2013
- Osaka Bio Fund to Invest 150 Million Yen in Genomix
December 26, 2013
- Mr Koshimizu of MREAC Expresses Concern about Increasing Number of MSLs at a Seminar on Recertification of Managers in Charge of MR Education
December 24, 2013
- Sanofi’s Moulding Picked as New Chair of EFPIA Japan
December 17, 2013
- FPMAJ Chief Renews His Calls to Institutionalize Premium
December 16, 2013
- JPMA Revises Rules for Preparing Product Information Brochures for the 1st Time in 5 years; Bans “Emphasis on Differences” from and “Slander” of Competitors’ Products
December 13, 2013
- Head of JAMS COI Committee Proposes Legislating Ethical Guidelines for Clinical Research
December 11, 2013
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…